Litcius/Paper detail

Synthesis of Some Novel Benzimidazole Derivatives as Anticancer Agentand Evaluation for CDK2 Inhibition Activity

Rania H. Abd El‐Hameed, Samar S. Fatahala, Amira I. Sayed

2021Medicinal Chemistry16 citationsDOI

Abstract

BACKGROUND: Thiobezimidazoles reveal various pharmacological activities due to similarities with many natural and synthetic molecules; they can easily interact with biomolecules of living systems. OBJECTIVE: A series of substituted 2-thiobezimidazoles have been synthesized. Twelve final compounds were screened for in vitro anti-cancer activities against sixty different cell lines. METHODS: The spectral data of the synthesized compounds were characterized. A docking study for active anticancer compounds and CDK2/CyclinA2 Kinase assay against standard reference; Imatinib, were performed. RESULTS: Two compounds (3c&3l) from the examined series revealed effective antitumor activity in vitro against two-cancer cell lines (Colon Cancer (HCT-116) and Renal Cancer (TK-10). The docking study of synthesized molecules discovered a requisite binding pose in the CDK-ATP binding pocket .3c &3l were promoted in the CDK2/CyclinA2 Kinase assay against standard reference Imatinib. CONCLUSION: Against all tested compounds; two compounds 3c &3l were found active against two types of cell-lines.

Topics & Concepts

BenzimidazoleDocking (animal)ChemistryIn vitroCyclin-dependent kinaseImatinibCell cultureBiological activityCyclin-dependent kinase 2KinaseCancer cellPharmacologyCombinatorial chemistryBiochemistryStereochemistryCancerCancer researchCellBiologyProtein kinase ACell cycleMedicineGeneticsMyeloid leukemiaOrganic chemistryNursingSynthesis and biological activitySynthesis and Reactivity of HeterocyclesQuinazolinone synthesis and applications
Synthesis of Some Novel Benzimidazole Derivatives as Anticancer Agentand Evaluation for CDK2 Inhibition Activity | Litcius